Breaking Finance News

N+1 Singer reiterated PureTech Health Plc (LON:PRTC) to Buy in a statement released earlier today.

N+1 Singer has reiterated PureTech Health Plc (LON:PRTC) to Buy in a report released on 9/25/2017.

Previously on 8/30/2017, Jefferies International reported about PureTech Health Plc (LON:PRTC) held steady the target price at 225.00GBX. At the time, this indicated a possible upside of 0.64%.

Yesterday PureTech Health Plc (LON:PRTC) traded -1.52% lower at 133.50GBX. The company’s 50-day moving average is 135.84GBX and its 200-day moving average is 123.36GBX. The last stock close price is up 5.38% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 22,300 shares of the stock were exchanged, down from an average trading volume of 31,395

See Chart Below

PureTech Health Plc (LON:PRTC)

PureTech Health Plc has a 52 week low of 110.00GBX and a 52 week high of 165.00GBX The company’s market cap is currently 0 GBX.

In addition to N+1 Singer reporting its target price, a total of 5 firms have reported on the stock. The consensus target price is 2.95GBX with 4 firms rating the stock a strong buy, 1 firm rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About PureTech Health Plc (LON:PRTC)

PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets. This segment includes subsidiary companies, which include Vedanta Biosciences, Inc., Gelesis, Inc., Akili Interactive Lab, Inc., Tal Medical, Inc., Karuna Pharmaceuticals, Inc., Entrega Inc. and Follica Incorporated. Businesses in the project phase businesses segment are those whose activities are focused on financing, sourcing and creating new product candidates and newly created businesses whose technologies are in the process of validation. This segment includes subsidiary companies, which include The Sync Project Inc., Sonde Health, Inc., Commense Inc., Alivio Therapeutics, Inc., Vor Biopharma Inc., Enlight Biosciences, LLC, Mandara Sciences, LLC and Knode Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.